ClinicalTrials.gg

Program

YK012

A development code.

Its studies are mostly in Glomerulonephritis, Membranous · Burkitt Lymphoma · Lupus Erythematosus, Systemic, led by Excyte Biopharma.

Furthest: phase 2, since Aug 26, 20245 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Excyte Biopharma55 open or runningphase 2since Aug 26, 2024Aug 19, 2024Dec 2026phase 1 · NCT06982729

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2024First study: phase 1 study in RecurrenceFirst studyNCT06565689 · 48 planned · China
  2. Aug 26, 2024Phase 2 study in Burkitt LymphomaNCT06580301 · 46 planned · China
  3. May 6, 2025Phase 1 study in Primary Membranous NephropathyNCT06982729 · 72 planned · China
  4. May 30, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07010835 · 189 planned · China
  5. Nov 14, 2025Phase 1 study in Primary Membranous NephropathyNCT07234474 · 66 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Primary Membranous NephropathyNCT06982729
  2. Dec 31, 2026Primary completion: phase 2 study in Burkitt LymphomaNCT06580301
  3. Jun 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07010835
  4. Oct 2028Primary completion: phase 1 study in Primary Membranous NephropathyNCT07234474

TargetBeta

CD19 →CD3E →read by rule
“A Phase I Study of YK012, a Humanized CD19 × CD3 Bispecific Antibody, in Participants With Very High-Risk, Refractory Primary Membranous Nephropathy”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07234474Primary Membranous Nephropathy1Not yet recruitingOct 202866
NCT07010835Lupus Erythematosus, Systemic · China2RecruitingJun 2027189
NCT06982729Primary Membranous Nephropathy · China1RecruitingDec 202672
NCT06580301Burkitt Lymphoma · China2RecruitingDec 31, 202646
NCT06565689Recurrence · China1RecruitingDec 202848

How it is read

Names in the registry

  • “YK012”, 5 entries

Codes read as this program: YK012.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.